Evidence map›Paper›PMID 20302960›Full record

ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2010

Reduced-intensity conditioning regimens for allogeneic transplantation in children with acute lymphoblastic leukemia.

Michael R Verneris, Mary Eapen, Reggie Duerst, Paul A Carpenter, Michael J Burke, B V Afanasyev, Morton J Cowan, Wensheng He, Robert Krance, Chi-Kong Li and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 45 citations in OpenAlex.

  1. Reduced-Intensity Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Solid Tumors in Pediatric and Young Adult Patients.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2017
    Trial
  2. Trial
  3. Article
  4. Article
  5. Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2017
    Article
  6. Article
  7. Article
  8. Article
  9. Transplantation conditioning regimens and outcomes after allogeneic hematopoietic cell transplantation in children and adolescents with acute lymphoblastic leukemia.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2013
    Article
  10. Outcome of myeloablative conditioning and unrelated donor hematopoietic cell transplantation for childhood acute lymphoblastic leukemia in third remission.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2011
    Article
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 11 institutions in 4 countries.

Michael R VernerisUniversity of Minnesota Medical Center, Minneapolis, Minnesota, USA.
Mary Eapen
Reggie Duerst
Paul A Carpenter
Michael J Burke
B V Afanasyev
Morton J Cowan
Wensheng He
Robert Krance
Chi-Kong Li
Poh-Lin Tan
John E Wagner
Stella M Davies
Medical College of Wisconsin · USUniversity of Minnesota · USBaylor College of Medicine · USChinese University of Hong Kong · CNCincinnati Children's Hospital Medical Center · USFirst Pavlov State Medical University of St. Petersburg · RUFred Hutch Cancer Center · USMemorial Medical Center · USNational University Hospital · SGUniversity of California San Francisco Medical Center · USUniversity of Minnesota Medical Center · US

Funding

Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
PB vs. BMU01HL069294 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI HOROWITZ, MARY MARESCA · 2001 to 2010
$63.3M
NCI NIH HHS U24 CA076518NCI NIH HHS U24-CA76518NHLBI NIH HHS 5U01HL069294NHLBI NIH HHS U01 HL069294
6 · The paper itself

Abstract

Reduced-intensity conditioning regimens have been used extensively in adults with hematologic malignancies. To address whether this is a feasible approach for children with acute lymphoblastic leukemia, we evaluated transplant outcomes in 38 recipients transplanted from 1995-2005 for whom this was their first transplant. The median age at transplant was 12 years, and 47% had performance scores <90%. Disease status was first complete remission (CR) in 13%, > or =CR2 in 60% of patients, and 22% had active disease at transplantation. Matched related donors were available for a third of patients, about half of whom received bone marrow (BM) and the others, peripheral blood progenitor cells. Sixty percent of unrelated donor transplant recipients received peripheral blood progenitor cells. The day-100 probability of grade II-IV acute graft-versus-host disease was 37% and the 3-year probability of chronic graft-versus-host disease, 26%. At 3 years, the probability of treatment-related mortality was 40%, relapse 37%, and disease-free survival 30%. These data indicate long-term DFS can be achieved using reduced-intensity conditioning regimens in children with acute lymphoblastic leukemia. Given the relatively small cohort, these findings must be validated in a larger population.

Indexed as

AdolescentChildChild, PreschoolCohort StudiesHematopoietic Stem Cell TransplantationHumansInfantPrecursor Cell Lymphoblastic Leukemia-LymphomaTransplantation ConditioningTransplantation, HomologousTreatment Outcome

Identifiers

PMID20302960
PMCPMC2904410
OpenAlexW1980900059

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.